




A**Day 22 post GBM8****B****Day 15 post GBM8**


Supplementary Figure 1. Pseudo-randomization before the start of treatment. Mice were divided into four treatment groups so that the average tumor-associated Fluc signal for each group is equal, in the AAV-sTRAIL experiment with a single i.c. injection (**A**; $p = 0.9955$) or multiple injections (**B**; $p > 0.9999$).

A

Day 36 post GBM8
2 weeks post AAV-sTRAIL

**B**

Day 71 post GBM8
7 weeks post AAV-sTRAIL



Supplementary Figure 2. AAVrh.8-sTRAIL combined with lanatoside C significantly reduces tumor size in GBM8-tumor bearing mice. (A) At 36 days post GBM8 injection, a significant difference is observed between animals treated with AAV-GFP control vector +/- lanatoside C and animals treated with AAV-sTRAIL +/- lanatoside C. All animals in the former groups had to be sacrificed due to tumor burden. (B) At 71 days post GBM8 injection, there is a significant difference in animals treated with AAV-sTRAIL + vehicle vs. AAV-sTRAIL + lan C. At this point, all animals in the control groups had been sacrificed due to tumor burden. (*p < 0.02, **p < 0.001).